Details
Stereochemistry | RACEMIC |
Molecular Formula | C13H15HgNO5.Na.HO |
Molecular Weight | 505.85 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[OH-].[Na+].COC(C[Hg+])CNC(=O)C1=C(OCC([O-])=O)C=CC=C1
InChI
InChIKey=WWKZBHGJCDECFG-UHFFFAOYSA-L
InChI=1S/C13H16NO5.Hg.Na.H2O/c1-9(18-2)7-14-13(17)10-5-3-4-6-11(10)19-8-12(15)16;;;/h3-6,9H,1,7-8H2,2H3,(H,14,17)(H,15,16);;;1H2/q;2*+1;/p-2
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/130827
Sources: https://www.ncbi.nlm.nih.gov/pubmed/130827
MERSALYL (Mersal) is an organomercury compound, mercurial diuretics that superseded by safer diuretics such as thiazides, and is hardly used anymore. Due to the idiosyncratic nature of mercury toxicity, the risk of severe disease and sudden death are unpredictable and frequently show no warning signs. Mercurial diuretics cause diuresis by reducing the reabsorption sodium in the ascending loop of Henle, thus causing more water being delivered to the distal convoluted tubule. Unfortunately, earlier physicians misconstrued hallmark symptoms of mercury poisoning such as excessive salivation as signs of mercury's efficacy, including up until the early 1960s when the use of mercurial diuretics was halted in medicine.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0006814 Sources: https://www.ncbi.nlm.nih.gov/pubmed/445225 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Mersal Approved UseUnknown |
Doses
Dose | Population | Adverse events |
---|---|---|
15 mL multiple, intravenous Dose: 15 mL Route: intravenous Route: multiple Dose: 15 mL Sources: |
unhealthy, 75 n = 1 Health Status: unhealthy Condition: carcinoma of the stomach Age Group: 75 Sex: M Population Size: 1 Sources: |
Other AEs: Bladder discomfort, Restlessness... Other AEs: Bladder discomfort Sources: Restlessness Muscle cramps Dehydration |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Bladder discomfort | 15 mL multiple, intravenous Dose: 15 mL Route: intravenous Route: multiple Dose: 15 mL Sources: |
unhealthy, 75 n = 1 Health Status: unhealthy Condition: carcinoma of the stomach Age Group: 75 Sex: M Population Size: 1 Sources: |
|
Dehydration | 15 mL multiple, intravenous Dose: 15 mL Route: intravenous Route: multiple Dose: 15 mL Sources: |
unhealthy, 75 n = 1 Health Status: unhealthy Condition: carcinoma of the stomach Age Group: 75 Sex: M Population Size: 1 Sources: |
|
Muscle cramps | 15 mL multiple, intravenous Dose: 15 mL Route: intravenous Route: multiple Dose: 15 mL Sources: |
unhealthy, 75 n = 1 Health Status: unhealthy Condition: carcinoma of the stomach Age Group: 75 Sex: M Population Size: 1 Sources: |
|
Restlessness | 15 mL multiple, intravenous Dose: 15 mL Route: intravenous Route: multiple Dose: 15 mL Sources: |
unhealthy, 75 n = 1 Health Status: unhealthy Condition: carcinoma of the stomach Age Group: 75 Sex: M Population Size: 1 Sources: |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/5849145
mersalyl 2 ml. intramuscularly, over a period of six days
Route of Administration:
Intramuscular
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1850465
Renal cortical slices (about 5 x 5 x 0.5 mm) from New Zealand white rabbits, fed a sodium-deficient rabbit Chow for 2 to 3 weeks, were prepared. Two or three slices were incubated at 37’C for two to three periods of 1 hr each, unless otherwise indicated, in 2 ml of medium that was continuously gassed with 100% 02. The composition of the standard incubation medium was (in mM): NaC1, 145; KC1, 5.5; CaCl2, 2.0; MgCl2, 1.0; glucose, 10; N-2-hydroxyethylenepiperazine-N-2-ethanesulfonic acid, 10. The pH was adjusted to 7.0. The Na+-free and Cl--free medium was prepared by substituting Na+ with K+, and Cl- with isethionate (2-hydroxyethanesulfonate), respectively. The Na+-free modified medium did not contain 2 mM CaCl2 but contained 2 mM EGTA. In this Na+-free, high K+ medium, Ca2+ was found to exert a marked inhibitory effect on renin secretion. Therefore, Ca2+ was excluded from the medium to avoid the complication of the inhibitory effect of Ca2+ on renin secretion superimposed on the stimulatory effect of EA. The first 1-hr incubation in the standard medium served as the control. For subsequent periods, slices were incubated in media containing different ionic compositions or with MERSALYL (10mkM-3mM). In parallel, slices were incubated in the standard medium without test reagents as the time control. At the end of each incubation period, medium was collected and renin activity was determined by radioimmunoassay of angiotensin I generated following incubation of an aliquot of collected medium with plasma of 48-hr nephrectomized rabbits.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C448
Created by
admin on Sat Dec 16 16:47:14 GMT 2023 , Edited by admin on Sat Dec 16 16:47:14 GMT 2023
|
||
|
WHO-VATC |
QC03BC01
Created by
admin on Sat Dec 16 16:47:14 GMT 2023 , Edited by admin on Sat Dec 16 16:47:14 GMT 2023
|
||
|
WHO-ATC |
C03BC01
Created by
admin on Sat Dec 16 16:47:14 GMT 2023 , Edited by admin on Sat Dec 16 16:47:14 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
207-748-9
Created by
admin on Sat Dec 16 16:47:14 GMT 2023 , Edited by admin on Sat Dec 16 16:47:14 GMT 2023
|
PRIMARY | |||
|
5X1IO031V8
Created by
admin on Sat Dec 16 16:47:14 GMT 2023 , Edited by admin on Sat Dec 16 16:47:14 GMT 2023
|
PRIMARY | |||
|
398
Created by
admin on Sat Dec 16 16:47:14 GMT 2023 , Edited by admin on Sat Dec 16 16:47:14 GMT 2023
|
PRIMARY | |||
|
DB09338
Created by
admin on Sat Dec 16 16:47:14 GMT 2023 , Edited by admin on Sat Dec 16 16:47:14 GMT 2023
|
PRIMARY | |||
|
6774
Created by
admin on Sat Dec 16 16:47:14 GMT 2023 , Edited by admin on Sat Dec 16 16:47:14 GMT 2023
|
PRIMARY | RxNorm | ||
|
4657
Created by
admin on Sat Dec 16 16:47:14 GMT 2023 , Edited by admin on Sat Dec 16 16:47:14 GMT 2023
|
PRIMARY | |||
|
CHEMBL1201330
Created by
admin on Sat Dec 16 16:47:14 GMT 2023 , Edited by admin on Sat Dec 16 16:47:14 GMT 2023
|
PRIMARY | |||
|
MERSALYL
Created by
admin on Sat Dec 16 16:47:14 GMT 2023 , Edited by admin on Sat Dec 16 16:47:14 GMT 2023
|
PRIMARY | |||
|
9806195
Created by
admin on Sat Dec 16 16:47:14 GMT 2023 , Edited by admin on Sat Dec 16 16:47:14 GMT 2023
|
PRIMARY | |||
|
C77560
Created by
admin on Sat Dec 16 16:47:14 GMT 2023 , Edited by admin on Sat Dec 16 16:47:14 GMT 2023
|
PRIMARY | |||
|
m7241
Created by
admin on Sat Dec 16 16:47:14 GMT 2023 , Edited by admin on Sat Dec 16 16:47:14 GMT 2023
|
PRIMARY | Merck Index | ||
|
SUB08779MIG
Created by
admin on Sat Dec 16 16:47:14 GMT 2023 , Edited by admin on Sat Dec 16 16:47:14 GMT 2023
|
PRIMARY | |||
|
100000081713
Created by
admin on Sat Dec 16 16:47:14 GMT 2023 , Edited by admin on Sat Dec 16 16:47:14 GMT 2023
|
PRIMARY | |||
|
D008634
Created by
admin on Sat Dec 16 16:47:14 GMT 2023 , Edited by admin on Sat Dec 16 16:47:14 GMT 2023
|
PRIMARY | |||
|
492-18-2
Created by
admin on Sat Dec 16 16:47:13 GMT 2023 , Edited by admin on Sat Dec 16 16:47:13 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD